Masterclass Certificate Biosimilars: Personalized Medicine Strategies
-- ViewingNowThe Masterclass Certificate Biosimilars: Personalized Medicine Strategies course is a comprehensive program that addresses the growing demand for specialized knowledge in the field of biosimilars. This course is vital for professionals seeking to stay updated on the latest advancements in personalized medicine and the development, regulatory, and commercialization aspects of biosimilars.
4,569+
Students enrolled
GBP £ 140
GBP £ 202
Save 44% with our special offer
ๅ ณไบ่ฟ้จ่ฏพ็จ
100%ๅจ็บฟ
้ๆถ้ๅฐๅญฆไน
ๅฏๅไบซ็่ฏไนฆ
ๆทปๅ ๅฐๆจ็LinkedInไธชไบบ่ตๆ
2ไธชๆๅฎๆ
ๆฏๅจ2-3ๅฐๆถ
้ๆถๅผๅง
ๆ ็ญๅพ ๆ
่ฏพ็จ่ฏฆๆ
โข Introduction to Biosimilars & Personalized Medicine: Defining biosimilars, understanding the concept of personalized medicine and its significance in the pharmaceutical industry. โข Regulatory Framework & Guidelines: Overview of regulatory frameworks and guidelines for biosimilars in major markets (US, EU, etc.), focusing on approval processes and requirements. โข Clinical Development & Trials: Discussing the methodologies and challenges in designing and implementing clinical trials for biosimilars, including pharmacokinetics, pharmacodynamics, and immunogenicity assessments. โข Manufacturing & Quality Control: Exploring the manufacturing process of biosimilars, emphasizing quality control, and comparing them to originator biologics. โข Intellectual Property & Patent Laws: Examining the role of intellectual property and patent laws in biosimilars development, including patent strategy and litigation. โข Pharmacoeconomics & Market Access: Understanding the economic impact of biosimilars on healthcare systems and payers, assessing market access strategies and pricing challenges. โข Interchangeability, Switching & Prescribing: Delving into the interchangeability, substitution, and switching considerations for biosimilars and originator biologics. โข Real-World Evidence & Post-Marketing Surveillance: Discussing real-world evidence and post-marketing surveillance for biosimilars, including monitoring adverse events and maintaining long-term safety profiles. โข Stakeholder Engagement & Collaboration: Addressing the importance of engagement and collaboration between all stakeholders involved in the development, approval, and use of biosimilars.
่ไธ้่ทฏ
ๅ ฅๅญฆ่ฆๆฑ
- ๅฏนไธป้ข็ๅบๆฌ็่งฃ
- ่ฑ่ฏญ่ฏญ่จ่ฝๅ
- ่ฎก็ฎๆบๅไบ่็ฝ่ฎฟ้ฎ
- ๅบๆฌ่ฎก็ฎๆบๆ่ฝ
- ๅฎๆ่ฏพ็จ็ๅฅ็ฎ็ฒพ็ฅ
ๆ ้ไบๅ ็ๆญฃๅผ่ตๆ ผใ่ฏพ็จ่ฎพ่ฎกๆณจ้ๅฏ่ฎฟ้ฎๆงใ
่ฏพ็จ็ถๆ
ๆฌ่ฏพ็จไธบ่ไธๅๅฑๆไพๅฎ็จ็็ฅ่ฏๅๆ่ฝใๅฎๆฏ๏ผ
- ๆช็ป่ฎคๅฏๆบๆ่ฎค่ฏ
- ๆช็ปๆๆๆบๆ็็ฎก
- ๅฏนๆญฃๅผ่ตๆ ผ็่กฅๅ
ๆๅๅฎๆ่ฏพ็จๅ๏ผๆจๅฐ่ทๅพ็ปไธ่ฏไนฆใ
ไธบไปไนไบบไปฌ้ๆฉๆไปฌไฝไธบ่ไธๅๅฑ
ๆญฃๅจๅ ่ฝฝ่ฏ่ฎบ...
ๅธธ่ง้ฎ้ข
่ฏพ็จ่ดน็จ
- ๆฏๅจ3-4ๅฐๆถ
- ๆๅ่ฏไนฆไบคไป
- ๅผๆพๆณจๅ - ้ๆถๅผๅง
- ๆฏๅจ2-3ๅฐๆถ
- ๅธธ่ง่ฏไนฆไบคไป
- ๅผๆพๆณจๅ - ้ๆถๅผๅง
- ๅฎๆด่ฏพ็จ่ฎฟ้ฎ
- ๆฐๅญ่ฏไนฆ
- ่ฏพ็จๆๆ
่ทๅ่ฏพ็จไฟกๆฏ
่ทๅพ่ไธ่ฏไนฆ